I'm structuring a legal memo as counsel for LumaBio, analyzing the warranty breach claim by examining whether the "300 vials per minute" specification creates an enforceable warranty obligation or represents a design rating subject to the acceptance test threshold of 285 vpm. The key tension is whether "rated throughput" is a binding specification under the conformity warranty or a nominal capacity that's satisfied by meeting the acceptance standard, and I'm working through how the contract language, course of performance, and industry context resolve this ambiguity.

The post-patch performance data shows the line consistently meets the 285 acceptance criteria (286–289 vpm), which supports LumaBio's position that any temporary nonconformity from the defective feed-control software has been cured, though there's a damages question around the six-week delay in deploying the patch and whether LumaBio can recover for the period of diminished capacity. I'm also flagging that the internal engineering chat about the architecture's ~288 vpm ceiling is relevant to fraud analysis but doesn't directly resolve the warranty scope question.

Now I'm turning to the pre-contract email and how the merger clause operates to exclude prior contradicting statements about "300 all day on your current film" from the integrated agreement. The representation about 300 throughput being a technical capability of the design is stronger for fraud — especially with the internal chat showing PrecisionFill knew the architecture maxed out around 288 and deliberately avoided documenting it, which suggests scienter or recklessness. The reasonable reliance defense is complicated: LumaBio's project leader knowingly accepted the 285 guarantee, suggesting non-reliance, but LumaBio's internal notes indicate it genuinely believed the 300 commitment was real and valuable. LumaBio also withheld its own film QC data showing defects, which raises unclean hands and muddies causation for the "on your current film" qualifier.

The fraud angle matters because liability caps and consequential damages exclusions don't apply to fraud or gross negligence — that's the gateway to recovering lost profits and lost customer orders. Damages would be measured as out-of-pocket loss or benefit of bargain depending on jurisdiction, though the economic loss rule might bar the fraud tort if it's purely coextensive with the contract breach, though fraudulent inducement claims are generally permitted. The 285 acceptance test functions as a conditional acceptance mechanism with specific test conditions like humidity ranges and compliant film, serving as the agreed benchmark for conformity.

The 300 rated throughput is a design rating with inherent ambiguity, but the express warranty covers conformity to written specifications which includes it. The most defensible reading is that 300 is nominal and 285 with the 3% tolerance is the agreed conformity measure, with the humidity and film conditions showing the parties understood performance depends on LumaBio-controlled variables. LumaBio will argue the acceptance test is a one-time gate rather than a cap on the 12-month warranty, and that stating 300 would be pointless if 285 were the standard. The acceptance certificate language — "subject to punch-list and sustained production validation" — indicates acceptance under the reasonable inspection rule, and while the reservation isn't an effective rejection, it preserves claims for latent defects and defeats any waiver argument, though the undefined criteria create ambiguity that course of performance might resolve.

PrecisionFill's remedial efforts and the technician's humidity explanations suggest both parties treated sustained production as a real obligation, which supports an implicit warranty duty beyond just the initial 285 reading. The 8 months of continued use and integration into the validated pharmaceutical process work against revocation — rejection is already off the table given the signed acceptance certificate and ongoing use, and revocation requires substantial impairment of value, which is hard to establish when post-patch runs hit 286–289 and meet acceptance criteria, representing only a ~4% shortfall from 300.

On notice, the 75-day delay is mitigated by PrecisionFill's technicians working on the problem from week one, giving them actual knowledge that likely satisfies the notice requirement. The humidity confusion delayed discovery of the software defect, and the day-25 email mentioning "contractual and legal remedies" provides earlier signaling of the breach, though there's some tension between service requests and formal breach notice — but actual knowledge and continued repair efforts favor LumaBio's position.

Now turning to essential purpose: the repair took three weeks of humidity confusion, then diagnosis, then six weeks for the patch. If 285 is the applicable standard, the line meets it after the patch, so the remedy succeeded and there's no failure of essential purpose — though the delay period itself may support damages. If 300 is the standard, PrecisionFill can't cure without a feeder redesign and has refused, which means the remedy fails of essential purpose, giving LumaBio full Article 2 remedies except that the consequential damages exclusion survives because it's expressly made independent of the remedy clause, unless unconscionability applies.

On damages, I'm looking at direct diminution (roughly 4% of the $4.8M purchase price, or around $190k based on the capacity shortfall), incidental costs like overtime and expedited labor (which PrecisionFill will fight as lost production but are more properly characterized as costs of dealing with nonconforming goods), and lost customer orders (excluded by contract unless fraud or willful misconduct applies). The $900k withholding is problematic because LumaBio likely didn't give proper notice of intent to deduct, and the amount probably exceeds provable damages anyway, exposing LumaBio to a breach claim.

On spoliation, the telemetry was overwritten after LumaBio's day-25 email signaling litigation, which triggered a preservation duty, but the automatic deletion without intent to deprive probably won't support an adverse inference — instead the court would likely bar PrecisionFill from relying on telemetry-based arguments and allow LumaBio to prove content through other means. PrecisionFill's defenses include humidity during the three-week period, the 18% film variance outside Schedule B specs, the merger clause, and the project leader's email undermining reliance, plus the interesting point that even compliant film rarely exceeded 290, which actually cuts against PrecisionFill's film excuse and supports LumaBio's fraud claim. Settlement is the realistic path here, with realistic recoverable damages in the $300k–$800k range against the $900k withholding, so the settlement zone is probably a modest credit plus engineering commitments like a feeder redesign at PrecisionFill's cost and a sustained-performance protocol.